Clinical Trial Update: Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

View source ↗

Summary

Real-world study assessing taletrectinib in advanced ROS1-positive non-small cell lung cancer after progression on entrectinib; the trial status is NOT_YET_RECR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rozlytrek (entrectinib)
• Taletrectinib (taletrectinib)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Non-small Lung Cancer | Status: NOT_YET_RECRUITING